We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Predicts Low Birth Weight

By LabMedica International staff writers
Posted on 04 Sep 2012
A protein found in the blood of pregnant women can predict if they are likely to have a fetus that does not grow properly. More...


The assay could lead to a widely available blood test that could help develop ways for improving the outcomes of women and their children who face this high risk of stillbirth and long-term health complications.

Scientists at the Ottawa Hospital Research Institute (ON, Canada) conducted a nested case-control study to examine circulating levels of Insulin Growth Factor Binding Protein 4 (IGBP-4) and other biomarkers by Western blot in early gestation in 36 women who went on to develop fetal growth restriction (FGR) and 36 controls having normal-weight babies.

The investigators found that IGFBP-4 was elevated in early pregnancy compared with nonpregnant women and women in later pregnancy, consistent with the presence of abundant extravillous trophoblasts and decidual cells that highly expressed IGFBP-4. High expression of pregnancy-associated plasma protein-A (PAPP-A) was observed in extravillous trophoblasts and decidual cells in early pregnancy but hardly detectable in the circulation at the same time. The women with high levels of IGFBP-4 were 22 times more likely to give birth to tiny babies, defined as the smallest 5% by weight for their gestational age, than women with normal levels of IGFBP-4.

Andrée Gruslin, MD, the lead author of the study, said, "Usually, we don’t find out until later in a pregnancy that a fetus isn’t growing properly, but this test can tell us in the first trimester if there’s likely to be a problem. By identifying these high-risk pregnancies early on, we will be able to monitor these women more closely and hopefully help them deliver a healthier baby.” Dr. Gruslin hopes that her studies on IGFBP-4 could lead to new approaches that would improve fetal growth in high-risk pregnancies. This condition, called Fetal Growth Restriction or Intrauterine Growth Restriction, is thought to affect 3%-5% of all pregnancies, and cause close to half of all stillbirths. The study was published on August 1, 2012, in the Journal of Clinical Endocrinology and Metabolism.

Related Links:
Ottawa Hospital Research Institute



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.